

Affymax Facts

Headquarters:

4001 Miranda Avenue
Palo Alto, CA 94304

(650) 812-8700 Main

Stock Listing:

NASDAQ: AFFY

Incorporated:

July 2001

Partner:

Takeda Pharmaceutical Company
Limited

Research Coverage:

Cowen and Company
Philip Nadeau, Ph.D.

Morgan Stanley
Steven Harr, M.D.

RBC Capital Markets (US)
Jason Kantor, Ph.D.

Thomas Weisel Partners
M. Ian Somaiya

Robert W. Baird & Co.
Chris Raymond

Summer Street Research Partners
Carol Werther

Corporate Contact:

Sylvia Wheeler
Executive Director
(650) 812-8861
investors@affymax.com

For additional information, visit
www.affymax.com

About Affymax

Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. The company's product candidate, Hematide[™], has been investigated in Phase 3 trials for the treatment of anemia associated with chronic renal failure.


Hematide[™]: Lead Product Candidate

Hematide[™] is an investigational (not yet approved for use) erythropoiesis-stimulating agent (ESA) that is being tested in clinical trials for the treatment of anemia associated with chronic renal failure (CRF). The investigational therapy has been investigated in Phase 3 studies in patients with CRF. Affymax and its development and commercialization partner Takeda Pharmaceuticals Co. Ltd., upon approval, plan to co-commercialize the product in the United States, while Takeda will be responsible for commercializing in the European Union.

The business opportunity for Hematide is significant. The worldwide anemia market is approximately \$11.5 billion, of which approximately \$4 billion is generated in renal indications in the United States. Globally, approximately \$7 billion accounts for treatment of anemia in dialysis and non-dialysis patients with the remaining \$5 billion attributable to other indications.¹ If proven safe and effective in clinical trials, Hematide is poised to be the first long-acting ESA in the U.S. market and may offer physicians and patients an alternative therapy to recombinant erythropoietin. Affymax believes the unique attributes of Hematide will contribute to its success in penetrating the ESA market.

How Hematide Works

Hematide is a novel synthetic, PEGylated peptidic compound that binds to and activates the erythropoietin receptor endogenous human erythropoietin (EPO), a protein produced by the kidneys to stimulate the production of oxygen-transporting red blood cells. In contrast to the current standard of care, recombinant protein-based ESAs, the unique molecular design of Hematide may provide for increased product stability, which potentially allows for room temperature storage in the office, during distribution and in patients' homes.



Hematide binds to and acts through the epoietin (EPO) receptor with potent in vitro and in vivo activity demonstrated in multiple species. The compound is PEGylated for increased stability and extended half-life.

Ongoing Phase 3 Clinical Studies

Affymax has conducted Phase 3 clinical trials of Hematide to treat anemia in patients with chronic renal failure. The Phase 3 program included four open-label, randomized controlled clinical trials involving a total of approximately 2,600 chronic renal failure patients, including those on dialysis and not on dialysis.

EMERALD 1 & 2

These trials are fully enrolled and include approximately 1,600 patients on dialysis who were previously-treated with Epogen. The trial was designed to evaluate the safety and efficacy of Hematide and its ability to maintain hemoglobin levels in a corrected range compared to epoetin alfa or epoetin beta when patients are switch from either of these epoetins to Hematide.

PEARL 1 & 2

PEARL 1 & 2 are fully enrolled. The studies include approximately 950 non-dialysis patients and were designed to evaluate the safety and efficacy of Hematide compared to darbepoetin alfa in correcting anemia and maintaining hemoglobin in a corrected range over time.

Anemia and Chronic Renal Failure

Anemia in CRF affects many individuals with Chronic Kidney Disease (CKD). According to the National Kidney Foundation, 26 million Americans – 1 in 9 U.S. adults – have CKD. Anemia develops in the early stages of CKD and worsens as patients progress towards total kidney failure and need a dialysis machine to eliminate waste and water from their blood. In severe or prolonged cases of anemia, the lack of oxygen in the blood can cause serious and sometimes fatal damage to the heart and other organs. Benefits of anemia correction in patients with CKD include decreased morbidity, hospitalization, and mortality.²



References:

1. IMS Health MIDAS, 2008
2. http://www.anemia.org/pdf/mon_Anemia_and_CKD.pdf

INVESTOR INFORMATION: This fact sheet is a summary of more detailed disclosure that can be found in Affymax's filings with the U.S. Securities and Exchange Commission and its press releases. This fact sheet contains forward-looking statements that involve risks and uncertainties, discussion of which can be found in Affymax's most recent Form 10-K, 10-Q, and 8-K and on www.affymax.com.

Executive Management

Arlene M. Morris

President and Chief Executive Officer

Paul B. Cleveland

Chief Financial Officer and Executive Vice President, Corporate Development

Ann-Marie Duliege, M.D., M.S.

Chief Medical Officer

Jeffrey H. Knapp

Chief Commercial Officer

Kay Slocum

Senior Vice President, Human Resources

Christine Conroy, Pharm.D.

Vice President, Regulatory Affairs and Good Clinical Practice Compliance

Tracy J. Dunn, Ph.D., J.D.

Vice President, Intellectual Property and Legal Affairs

Carol Francisco, Ph.D.

Vice President, Biostatistics and Data Management

Steven Love

Vice President, Finance

Grace U. Shin, J.D.

General Counsel

Robert F. Venteicher, Ph.D.

Senior Vice President, Technical Operations

Board of Directors

R. Lee Douglas

Independent Biotechnology Consultant and Visiting Scholar, UC Berkeley

Nicholas Galakatos, Ph.D.

Managing Director, Clarus Ventures

Christi van Heek

Managing Director, BIO POINT Group

Kathleen LaPorte

Managing Director, New Leaf Venture Partners

Keith R. Leonard

President and CEO, Kythera Biopharmaceuticals

Ted W. Love, M.D.

Independent Member of Board of Directors

Arlene M. Morris

President and CEO, Affymax, Inc.

Daniel K. Spiegelman

Independent Member of Board of Directors

John P. Walker

CEO, iZumi Bio, Inc.